VERVE-102 for myocardial infarction

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 24 Sep 2026: Trial registered, NCT07839936
  2. 24 Sep 2026: Trial started, NCT07839936

The trials

NCT07839936: A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease

State
Under way
Phase
Phase 2
People
175 planned
Started
24 Sep 2026
Primary completion
Aug 2028
Arms
VERVE-102 Dose 1, VERVE-102 Dose 2, VERVE-102 Dose 3
Results
None posted
  1. 24 Sep 2026: Trial registered
  2. 24 Sep 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.